(Q35917368)

11 August 2017

1 reference

title

Therapeutic options for human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus-related disorders (English)

1 reference

11 August 2017

2

Giovanna Tosato

1 reference

11 August 2017

Yoshiyasu Aoki

1

1 reference

11 August 2017

publication date

1 April 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

213-225

1 reference

Pathogenesis and manifestations of human herpesvirus-8-associated disorders

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

AIDS across Europe, 1994-98: the EuroSIDA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

AIDS-associated Kaposi's sarcoma (KS) cells express oncostatin M (OM)-specific receptor but not leukemia inhibitory factor/OM receptor or interleukin-6 receptor. Complete block of OM-induced KS cell growth and OM binding by anti-gp130 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Viral G protein-coupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Clinical aspects and management of AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Targeted inhibition of angiogenic factors in AIDS-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Vascular endothelial growth factor/vascular permeability factor in the pathogenesis of primary effusion lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Recent advances in the treatment of AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Successful treatment of human immunodeficiency virus-related Castleman's disease: a case report and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Novel association of haemophagocytic syndrome with Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

A pilot study of cidofovir in patients with kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Multicentric Castleman's disease treated with antivirals and immunosuppressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Validating survivin as a cancer therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Rituximab therapy for HIV-associated Castleman disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.213

21 January 2018

Identifiers

DOI

10.1586/14787210.2.2.213

1 reference

11 August 2017

1 reference